Aceminib outperforms standard TKIs in phase III chronic myeloid leukemia trial

Aceminibhas been shown to have superior efficacy to standard of care tyrosine kinase inhibitors(TKIs). The trial, which compared aceminib with first- and second-generation TKIs, marks a major advance in chronic myeloid management and brings new hope to patients.

The trial, targeting patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia chronic phase(Ph+ CML-CP), met its primary endpoint. Compared with standard TKIs including imatinib, nilotinib, dasatinib and bosutinib, aximinib showed a higher rate of major molecular response (MMR) at week 48. This finding is not only clinically significant, but also statistically significant, demonstrating that Asiminib has a clear advantage in achieving molecular response targets in CML patients.

Aceminib performed well in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia chronic phase (Ph+ CML-CP), with fewer adverse events and treatment interruptions compared with standard TKIs. This is particularly important given that intolerance and adverse events are the main reasons for discontinuing TKI treatment. Currently, more than 60%of patients with newly diagnosed chronic myelogenous leukemia fail to achieve the molecular response goal of 12 months, primarily due to these challenges.

The ASC4FIRSTtrial(NCT04971226) was a Phase III, multicenter, open-label, randomized study comparing oral aceminib 80 in 405 adult patients. mg QDwith first- or second-generationTKIs selected by the investigator. The primary endpoint is based on reaching week 48Proportion of patients with MMR, comparing the efficacy of asciminib with selected TKIs. The study also evaluated secondary safety and efficacy endpoints, including time to treatment failure and overall survival.

Aceminibis the first CML treatment option for ABLmyristoyl cyst. It is approved in more than 60 countries for use in patients who have received two or more prior treatments with tki and is being studied in multiple lines of treatment with Ph+ CML-CP. The ongoing trial, with the next data readout scheduled for week 96, will continue to evaluate the long-term efficacy and safety of aceminib.